171 related articles for article (PubMed ID: 38348830)
21. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
[TBL] [Abstract][Full Text] [Related]
22. Going off antiretroviral treatment in a closely monitored HIV "cure" trial: longitudinal assessments of acutely diagnosed trial participants and decliners.
Henderson GE; Waltz M; Meagher K; Cadigan RJ; Jupimai T; Isaacson S; Ormsby NQ; Colby DJ; Kroon E; Phanuphak N; Ananworanich J; Peay HL
J Int AIDS Soc; 2019 Mar; 22(3):e25260. PubMed ID: 30869203
[TBL] [Abstract][Full Text] [Related]
23. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS
Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074
[TBL] [Abstract][Full Text] [Related]
24. "We are looking at the future right now": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States.
Dubé K; Kanazawa J; Roebuck C; Johnson S; Carter WB; Dee L; Peterson B; Lynn KM; Lalley-Chareczko L; Hiserodt E; Kim S; Rosenbloom D; Evans BR; Anderson M; Hazuda DJ; Shipley L; Bateman K; Howell BJ; Mounzer K; Tebas P; Montaner LJ
HIV Res Clin Pract; 2022 Dec; 23(1):120-135. PubMed ID: 35348047
[TBL] [Abstract][Full Text] [Related]
25. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells.
Hendricks CM; Cash MN; Tagliamonte MS; Riva A; Brander C; Llano A; Salemi M; Stevenson M; Mavian C
Microbiol Spectr; 2022 Aug; 10(4):e0135322. PubMed ID: 35699458
[TBL] [Abstract][Full Text] [Related]
26. "I Would Absolutely Need to Know That My Partner Is Still Going to be Protected": Perceptions of HIV Cure-Related Research Among Diverse HIV Serodifferent Couples in the United States.
Dubé K; Agarwal H; Stockman JK; Auerbach JD; Sauceda JA; Conroy AA; Johnson MO
AIDS Res Hum Retroviruses; 2023 Aug; 39(8):400-413. PubMed ID: 35972752
[TBL] [Abstract][Full Text] [Related]
27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
28. Acute HIV-1 infection viremia associate with rebound upon treatment interruption.
Mdluli T; Li Y; Pinyakorn S; Reeves DB; Cardozo-Ojeda EF; Yates A; Intasan J; Tipsuk S; Phanuphak N; Sacdalan C; Colby DJ; Kroon E; Crowell TA; Thomas R; Robb ML; Ananworanich J; de Souza M; Phanuphak P; Stieh DJ; Tomaka FL; Trautmann L; Ake JA; Hsu DC; Francisco LV; Vasan S; Rolland M
Med; 2022 Sep; 3(9):622-635.e3. PubMed ID: 35870446
[TBL] [Abstract][Full Text] [Related]
29. Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model.
Goswami R; Nelson AN; Tu JJ; Dennis M; Feng L; Kumar A; Mangold J; Mangan RJ; Mattingly C; Curtis AD; Obregon-Perko V; Mavigner M; Pollara J; Shaw GM; Bar KJ; Chahroudi A; De Paris K; Chan C; Van Rompay KKA; Permar SR
mBio; 2019 Sep; 10(5):. PubMed ID: 31488511
[TBL] [Abstract][Full Text] [Related]
30. Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control.
Jain A; Canepa GE; Liou ML; Fledderman EL; Chapoval AI; Xiao L; Mukherjee I; Balogun BM; Huaman-Vergara H; Galvin JA; Kumar PN; Bordon J; Conant MA; Boyle JS
Front Med (Lausanne); 2024; 11():1342476. PubMed ID: 38808136
[TBL] [Abstract][Full Text] [Related]
31. Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.
Zheng L; Tierney C; Bosch RJ
Curr HIV/AIDS Rep; 2021 Oct; 18(5):475-482. PubMed ID: 34213731
[TBL] [Abstract][Full Text] [Related]
32. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.
Palich R; Ghosn J; Chaillon A; Boilet V; Nere ML; Chaix ML; Delobel P; Molina JM; Lucht F; Bouchaud O; Rieux V; Thiebaut R; Levy Y; Delaugerre C; Lelievre JD;
AIDS; 2019 Feb; 33(2):279-284. PubMed ID: 30325777
[TBL] [Abstract][Full Text] [Related]
33. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
[TBL] [Abstract][Full Text] [Related]
34. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
[TBL] [Abstract][Full Text] [Related]
36. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.
Henderson GE; Peay HL; Kroon E; Cadigan RJ; Meagher K; Jupimai T; Gilbertson A; Fisher J; Ormsby NQ; Chomchey N; Phanuphak N; Ananworanich J; Rennie S
J Med Ethics; 2018 Apr; 44(4):270-276. PubMed ID: 29127137
[TBL] [Abstract][Full Text] [Related]
37. Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.
Dubé K; Eskaf S; Barr L; Palm D; Hogg E; Simoni JM; Sugarman J; Brown B; Sauceda JA; Henley L; Deeks S; Fox L; Gandhi RT; Smith D; Li JZ
AIDS Res Hum Retroviruses; 2022 Jun; 38(6):510-517. PubMed ID: 35323030
[TBL] [Abstract][Full Text] [Related]
38. Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366.
Dubé K; Hosey L; Starr K; Barr L; Evans D; Hoffman E; Campbell DM; Simoni J; Sugarman J; Sauceda J; Brown B; Diepstra KL; Godfrey C; Kuritzkes DR; Wohl DA; Gandhi R; Scully E
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):268-282. PubMed ID: 32160755
[TBL] [Abstract][Full Text] [Related]
39. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.
Peay HL; Rennie S; Cadigan RJ; Gwaltney A; Jupimai T; Phanuphak N; Kroon E; Colby DJ; Ormsby N; Isaacson SC; Vasan S; Sacdalan C; Prueksakaew P; Benjapornpong K; Ananworanich J; Henderson GE
AIDS Behav; 2022 May; 26(5):1504-1516. PubMed ID: 34997386
[TBL] [Abstract][Full Text] [Related]
40. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.
Pannus P; Rutsaert S; De Wit S; Allard SD; Vanham G; Cole B; Nescoi C; Aerts J; De Spiegelaere W; Tsoumanis A; Couttenye MM; Herssens N; De Scheerder MA; Vandekerckhove L; Florence E
J Int AIDS Soc; 2020 Feb; 23(2):e25453. PubMed ID: 32107887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
